Author: Healio ophthalmology

Leiter’s Compounding Pharmacy recalls bevacizumab lots

Leiter’s Compounding Pharmacy has voluntarily issued a nationwide recall of three lots of sterile products due to concerns regarding its independent testing lab, Front Range Laboratories, according to a release from the U.S. Food and Drug Administration.The lots being recalled are bevacizumab Lot No. 08052013@1, expiry 11/03/13; bevacizumab Lot No. 08052013@4, expiry 11/03/13; and lidocaine/phenylephrine Lot No. 07302013@6, expiry 10/28/13.

Surgical density, part 1: Reading the speedometer of your practice’s performance

Most eye surgeons want to do more surgery and spend less time in the clinic. Unfortunately, for those doctors who don’t enjoy clinic time as much as operating room time, surgical volume is directly linked to clinic time: See more patients and you’ll find more cases, obviously.But that’s only half of the story. Your personal surgical caseloads also depend on how many clinic patients you personally have to see to find each surgical case: your “surgical density.”  

Graves’ ophthalmopathy linked to dry eye disease, corneal sensitivity loss

Early-stage Graves ophthalmopathy was associated with clinically significant dry eye disease and reduced corneal sensitivity, according to a study.“[Graves’ disease] should be considered in the differential diagnosis for patients presenting with dry eyes and warrants further investigation, even in the absence of other clinical symptoms,” the study authors said.

BLOG: Good news on Azasite

We interrupt our regularly scheduled blog post on the physician’s role in diagnosing dry eye to report some fantastic news: Merck has announced that it will continue to make and sell Azasite. If you take care of patients with dry eye, especially those who could be characterized as having some sort of meibomian gland disease (MGD) resulting in a dysfunctional tear syndrome, you were worried about this issue.

Panretinal photocoagulation has minimal effect on corneal nerve density, sensitivity

Panretinal photocoagulation had an insignificant effect on corneal sub-basal nerve density and corneal sensitivity in diabetic patients, a study found.“The current study suggests that [panretinal photocoagulation] does not compromise the integrity of the corneal [sub-basal nerve plexus] and purely from the corneal perspective remains a relatively safe treatment modality in the treatment of [diabetic retinopathy],” the study authors said.

Waring Medal awarded for emerging refractive surgical technique

NEW YORK — The 2013 Waring Medal was awarded to Jesper Ø. Hjortdal, MD, DrMedSci, PhD, for his new refractive surgical technique for myopia patients.  “LASIK is very successful, but you can run into problems with epithelial ingrowth, flap striae or flap dislocation,” Hjortdal said at OSN New York 2013. “Instead of replacing the corneal tissue [in this procedure], you remove it.”

UVA, riboflavin cross-linking in treatment of infectious keratitis needs more testing

NEW YORK — UVA and riboflavin cross-linking could be considered for infectious keratitis treatments for better visual outcomes, but more studies are needed, according to a speaker here. Such methods are important to consider because only about half of patients report good visual outcomes when using traditional treatment methods after a corneal infection, Penny A. Asbell, MD, MBA, FACS said at OSN New York 2013. New possibilities also are needed because of increasing multidrug resistance to antibiotics and reduced effectiveness because antibiotic and antifungal agents often do not penetrate tissue (Read more...)

PRK offers advantages over LASIK, speaker says

NEW YORK — Photorefractive keratectomy can offer results comparable to LASIK surgery without some of the risks, according to a speaker here.In both the short and long term, photorefractive keratectomy (PRK) outcomes are similar to LASIK while eliminating flap concerns and reducing the likelihood of ectasia, Christopher E. Starr, MD, FACS, said at OSN New York 2013. PRK also now results in less pain than traditionally has been associated with the procedure and is an easier, cheaper and quicker surgery to perform than LASIK.

Early experience with new cataract surgery platform: Video with Richard L. Lindstrom, MD

NEW YORK — Richard L. Lindstrom, MD, discusses his early experience with the Alcon Centurion cataract surgery platform from OSN New York 2013.”I’ve done about 50 cases with it now,” Lindstrom said of the recently announced device. “The active fluidics, … maintaining a more stable chamber, setting whatever you want for IOP is, to me, definitely an advance.”

European patent awarded for Sjögren’s syndrome drug candidate

OphthaliX recently announced that its parent company, Can-Fite BioPharma, has been granted a patent by the European Patent Office for its drug candidate CF101 for treatment of Sjögren’s syndrome in Europe until 2025.The A3 adenosine receptor agonist is a novel small molecule, orally bioavailable drug that displayed efficacy and safety during phase 2 clinical studies, according to a press release.